A growing body of research links schizophrenia, bipolar disorder, and major depressive disorder to significantly elevated risks of developing neurological conditions, including Parkinson disease, dementia, and stroke. The connection is not new in psychiatric literature, but a cluster of large-scale studies, including one published in November 2025, sharpens the picture: neurological diagnoses often surface years after a severe mental illness diagnosis, suggesting a long-running biological or treatment-related process, rather than coincidence. For the roughly 1 in 20 adults living with a severe mental illness, the findings raise urgent questions about whether standard psychiatric care does enough to protect long-term brain health.
Bipolar Disorder and the Parkinson Risk
Among the most striking associations is the link between bipolar disorder and later Parkinson disease. A systematic review and meta-analysis in JAMA Neurology, covering seven observational datasets and 4,374,211 participants, found a pooled odds ratio of approximately 3.35 for idiopathic Parkinson disease among people with a prior bipolar disorder diagnosis. That means people with bipolar disorder were more than three times as likely to develop Parkinson disease compared to those without the psychiatric condition, even after adjustments for demographic and clinical confounders. The effect size is large enough that it cannot be dismissed as an artifact of surveillance bias or diagnostic enthusiasm.
Individual country-level studies reinforce that estimate and add temporal detail. A nationwide Taiwanese cohort tracked 56,340 bipolar disorder patients against 225,360 matched controls from 2001 through 2011, finding Parkinson disease incidence of 0.7% in the bipolar group versus 0.1% in controls, with an adjusted hazard ratio of 6.78. A separate Finnish register-based case-control study of 22,189 incident Parkinson disease cases diagnosed between 1996 and 2015 showed the elevated risk remained visible even with a roughly 20-year lag between bipolar diagnosis and Parkinson onset, with an adjusted odds ratio of approximately 2.32 at an 8-year lag window. The persistence of risk across decades weakens the argument that early Parkinson symptoms are simply being misclassified as mood episodes and instead points toward shared neurodegenerative pathways, inflammatory mechanisms, or cumulative effects of treatment and illness burden.
Dementia Risk Across Multiple Diagnoses
The neurological toll extends well beyond Parkinson disease. A cohort of 84,824 middle-aged adults directly compared schizophrenia, bipolar disorder, and major depressive disorder against subsequent dementia risk within a single analytic framework, finding elevated rates across all three diagnostic categories, with the highest relative risks in schizophrenia. A meta-analysis in Acta Psychiatrica Scandinavica estimated the pooled odds ratio for dementia in bipolar disorder at approximately 2.96, nearly tripling the baseline risk and suggesting that mood instability, recurrent episodes, or shared vascular and metabolic factors may contribute to long-term cognitive decline. These findings converge with clinical observations that cognitive complaints in severe mood and psychotic disorders often precede formal dementia diagnoses by many years.
Newer work has begun to map the temporal sequence more precisely. Research published in BMJ Mental Health in June 2024 concluded that psychiatric disorders are associated with increased dementia risk detectable years before the dementia diagnosis itself, with elevated hazard ratios present more than a decade in advance according to longitudinal registry analyses. This pattern raises the possibility that the psychiatric condition either accelerates neurodegeneration or shares common upstream triggers, such as chronic inflammation, cerebrovascular injury, or early-life adversity. It also complicates clinical decision-making: when a middle-aged patient with bipolar disorder or schizophrenia shows subtle cognitive decline, clinicians must consider both the psychiatric illness trajectory and the possibility of prodromal dementia, rather than attributing all changes to mood or psychosis alone.
Stroke, Mortality, and the Wider Burden
Stroke risk follows a similar and equally concerning pattern. A meta-analysis drawing on 36 cohorts and approximately 25.5 million individuals, with a literature search conducted through April 2024, found that schizophrenia was associated with a relative risk for stroke of approximately 1.74, while bipolar disorder carried a relative risk of about 1.65. Those figures translate to a 65% to 74% higher stroke risk compared to the general population, a gap large enough to demand clinical attention but one that rarely receives it in routine psychiatric practice. Traditional vascular risk factors (smoking, hypertension, diabetes, and dyslipidemia) are more prevalent in people with severe mental illness, but the magnitude of the association suggests that lifestyle alone does not fully explain the excess burden.
The broader context is grim. Multiple studies have documented excess mortality among people with severe mental illness, though a review in Frontiers in Psychiatry noted that the data on the mortality gap remain fairly inconsistent across countries and time periods. What is consistent is that individuals with severe mental illness face a heightened risk of somatic comorbidity, which compounds the neurological risks and creates a cycle of declining physical and cognitive health. Fragmented healthcare systems, in which psychiatric and medical care operate in parallel rather than in concert, may obscure the true scale of this interaction. Patients with schizophrenia or bipolar disorder often see psychiatrists far more frequently than primary care clinicians, yet stroke prevention and dementia screening usually sit outside the traditional remit of mental health services.
Temporal Patterns and Treatment Trade-offs
Emerging evidence suggests that the timing of neurological diagnoses relative to severe mental illness is not random. A study published on November 4, 2025, in BMJ Mental Health examined the prevalence of neurological disorders among adults with schizophrenia, bipolar disorder, and severe recurrent depression using linked national registries. The authors reported that a higher prevalence of neurological conditions first emerged in the years immediately following a severe mental illness diagnosis and continued to rise over the subsequent decade. Notably, the excess risk persisted even after excluding individuals whose neurological diagnosis predated or closely followed their psychiatric diagnosis, arguing against simple reverse causality in which early neurodegenerative changes masquerade as psychiatric symptoms.
These temporal patterns sharpen the focus on treatment trade-offs. Antipsychotic and mood-stabilizing medications are lifesaving for many patients, reducing suicide risk, stabilizing mood, and preventing psychotic relapses that can devastate social and occupational functioning. At the same time, long-term exposure to some agents has been associated with metabolic syndrome, weight gain, and cardiovascular complications, all of which may feed into stroke and dementia risk. A retrospective cohort of adults aged 50 or older with schizophrenia or schizoaffective disorder, followed for up to 12 years, found that cumulative dementia incidence among those prescribed antipsychotics reached 7.9%, compared with 5.5% among those not prescribed them, yielding an adjusted hazard ratio of approximately 1.92. Confounding by indication is a major concern. Patients with more severe illness are both more likely to receive antipsychotics and more likely to experience neurocognitive decline, but the signal underscores the need to weigh psychiatric stabilization against potential long-term neurological costs.
Rethinking Care: From Surveillance to Prevention
Clinicians and health systems are beginning to ask whether standard models of psychiatric care adequately address these intertwined risks. Observational work using primary care and hospital records has shown that people with severe mental illness frequently miss out on routine cardiovascular and metabolic screening, even as their prescriptions and diagnoses place them in high-risk categories. An analysis of UK electronic health records found that neurological and cardiometabolic conditions were under-recognized in patients with psychotic and bipolar disorders at the time of psychiatric assessment, with systematic gaps in blood pressure monitoring, lipid testing, and cognitive evaluation documented in baseline clinical encounters. These omissions mean that opportunities to modify vascular risk factors, through smoking cessation, antihypertensive therapy, or diabetes management, are often lost during the very years when prevention could have the greatest impact on later-life brain health.
Several research groups have proposed more integrated screening strategies. One population-based study used registry data and standardized diagnostic codes to compare the prevalence of neurological conditions in people with and without severe mental illness, applying logistic regression models to adjust for age, sex, and socioeconomic status. The authors argued that routine psychiatric follow-up visits could serve as a platform for systematic assessment of stroke risk scores, cognitive complaints, and early parkinsonian signs, with clear referral pathways to neurology and primary care when red flags emerge. Translating these proposals into practice will require changes in training, reimbursement, and clinical culture, but the epidemiological evidence leaves little doubt that severe mental illness and neurological disease are deeply entangled over the life course.
Taken together, the current literature reframes severe mental illness as a condition with profound neurological implications that unfold over decades. The elevated risks of Parkinson disease, dementia, and stroke are not inevitable outcomes for every patient, but they are common enough, and well documented enough, to justify proactive surveillance and aggressive management of modifiable risk factors. As more longitudinal data accumulate, the challenge for clinicians and policymakers will be to move beyond documenting these associations toward building care models that treat psychiatric and neurological health as inseparable parts of the same clinical story.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
